PURPOSE: The epidermal growth factor receptor (EGFR) is overexpressed in several types of cancer and its inhibition can effectively inhibit tumour progression. The purpose of this study was to design an EGFR-specific imaging probe that combines efficient tumour targeting with rapid systemic clearance to facilitate non-invasive assessment of EGFR expression. METHODS: Genetic fusion of a single-chain antibody fragment with the SNAP-tag produced a 48-kDa antibody derivative that can be covalently and site-specifically labelled with substrates containing 0 (6)-benzylguanine. The EGFR-specific single-chain variable fragment (scFv) fusion protein 425(scFv)SNAP was labelled with the near infrared (NIR) dye BG-747, and its accumulation, specificity and kinetics were monitored using NIR fluorescence imaging in a subcutaneous pancreatic carcinoma xenograft model. RESULTS: The 425(scFv)SNAP fusion protein accumulates rapidly and specifically at the tumour site. Its small size allows efficient renal clearance and a high tumour to background ratio (TBR) of 33.2 +/- 6.3 (n = 4) 10 h after injection. Binding of the labelled antibody was efficiently competed with a 20-fold excess of unlabelled probe, resulting in an average TBR of 6 +/- 1.35 (n = 4), which is similar to that obtained with a non-tumour-specific probe (5.44 +/- 1.92, n = 4). When compared with a full-length antibody against EGFR (cetuximab), 425(scFv)SNAP-747 showed significantly higher TBRs and complete clearance 72 h post-injection. CONCLUSION: The 425(scFv)SNAP fusion protein combines rapid and specific targeting of EGFR-positive tumours with a versatile and robust labelling technique that facilitates the attachment of fluorophores for use in optical imaging. The same approach could be used to couple a chelating agent for use in nuclear imaging.
PURPOSE: The epidermal growth factor receptor (EGFR) is overexpressed in several types of cancer and its inhibition can effectively inhibit tumour progression. The purpose of this study was to design an EGFR-specific imaging probe that combines efficient tumour targeting with rapid systemic clearance to facilitate non-invasive assessment of EGFR expression. METHODS: Genetic fusion of a single-chain antibody fragment with the SNAP-tag produced a 48-kDa antibody derivative that can be covalently and site-specifically labelled with substrates containing 0 (6)-benzylguanine. The EGFR-specific single-chain variable fragment (scFv) fusion protein 425(scFv)SNAP was labelled with the near infrared (NIR) dye BG-747, and its accumulation, specificity and kinetics were monitored using NIR fluorescence imaging in a subcutaneous pancreatic carcinoma xenograft model. RESULTS: The 425(scFv)SNAP fusion protein accumulates rapidly and specifically at the tumour site. Its small size allows efficient renal clearance and a high tumour to background ratio (TBR) of 33.2 +/- 6.3 (n = 4) 10 h after injection. Binding of the labelled antibody was efficiently competed with a 20-fold excess of unlabelled probe, resulting in an average TBR of 6 +/- 1.35 (n = 4), which is similar to that obtained with a non-tumour-specific probe (5.44 +/- 1.92, n = 4). When compared with a full-length antibody against EGFR (cetuximab), 425(scFv)SNAP-747 showed significantly higher TBRs and complete clearance 72 h post-injection. CONCLUSION: The 425(scFv)SNAP fusion protein combines rapid and specific targeting of EGFR-positive tumours with a versatile and robust labelling technique that facilitates the attachment of fluorophores for use in optical imaging. The same approach could be used to couple a chelating agent for use in nuclear imaging.
Authors: Paul J Yazaki; Thewodros Kassa; Chia-wei Cheung; Desiree M Crow; Mark A Sherman; James R Bading; Anne-Line J Anderson; David Colcher; Andrew Raubitschek Journal: Nucl Med Biol Date: 2008-02 Impact factor: 2.408
Authors: Florian Kampmeier; Markus Ribbert; Thomas Nachreiner; Sofia Dembski; Florent Beaufils; Andreas Brecht; Stefan Barth Journal: Bioconjug Chem Date: 2009-05-20 Impact factor: 4.774
Authors: Kirk P Withrow; John P Gleysteen; Ahmad Safavy; Joni Skipper; Renee A Desmond; Kurt Zinn; Eben L Rosenthal Journal: Otolaryngol Head Neck Surg Date: 2007-11 Impact factor: 3.497
Authors: Douglas W Schneider; Tara Heitner; Bruno Alicke; David R Light; Kirk McLean; Noboru Satozawa; Gordon Parry; Jeongsoo Yoo; Jason S Lewis; Renate Parry Journal: J Nucl Med Date: 2009-02-17 Impact factor: 10.057
Authors: Daniela Bruell; Christiane J Bruns; Maksim Yezhelyev; Michael Huhn; Jürgen Müller; Ivan Ischenko; Rainer Fischer; Ricarda Finnern; Karl-Walter Jauch; Stefan Barth Journal: Int J Mol Med Date: 2005-02 Impact factor: 5.314
Authors: Angel M Cuesta; David Sánchez-Martín; Laura Sanz; Jaume Bonet; Marta Compte; Leonor Kremer; Francisco J Blanco; Baldomero Oliva; Luis Alvarez-Vallina Journal: PLoS One Date: 2009-04-29 Impact factor: 3.240
Authors: Judith Niesen; Hannes Brehm; Christoph Stein; Nina Berges; Alessa Pardo; Rainer Fischer; Andre Ten Haaf; Stefan Gattenlöhner; Mehmet K Tur; Stefan Barth Journal: J Cancer Res Clin Oncol Date: 2014-11-30 Impact factor: 4.553
Authors: Verena von Felbert; Dirk Bauerschlag; Nicolai Maass; Karen Bräutigam; Ivo Meinhold-Heerlein; Mira Woitok; Stefan Barth; Ahmad Fawzi Hussain Journal: J Cancer Res Clin Oncol Date: 2016-02-03 Impact factor: 4.553
Authors: Judith Niesen; Christoph Stein; Hannes Brehm; Grit Hehmann-Titt; Rolf Fendel; Georg Melmer; Rainer Fischer; Stefan Barth Journal: J Cancer Res Clin Oncol Date: 2015-04-22 Impact factor: 4.322
Authors: Claudia Kessler; Alessa Pardo; Mehmet K Tur; Stefan Gattenlöhner; Rainer Fischer; Katharina Kolberg; Stefan Barth Journal: J Cancer Res Clin Oncol Date: 2017-06-30 Impact factor: 4.322
Authors: Haibiao Gong; Joy L Kovar; Brenda Baker; Aihua Zhang; Lael Cheung; Daniel R Draney; Ivan R Corrêa; Ming-Qun Xu; D Michael Olive Journal: PLoS One Date: 2012-03-30 Impact factor: 3.240